Determination of melanotan‐II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration | Zendy

Mock S. | Zendy; Shen X. | Zendy; Tamvakopoulos C. | Zendy

Premium

Determination of melanotan‐II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration

Author(s) -

Mock S.,

Shen X.,

Tamvakopoulos C.

Publication year - 2002

Publication title -

rapid communications in mass spectrometry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.528

H-Index - 136

eISSN - 1097-0231

pISSN - 0951-4198

DOI - 10.1002/rcm.847

Subject(s) - chemistry , chromatography , pharmacokinetics , analyte , solid phase extraction , tandem mass spectrometry , extraction (chemistry) , mass spectrometry , liquid chromatography–mass spectrometry , detection limit , selected reaction monitoring , pharmacology , medicine

A method is described for the determination of melanotan‐II (MT‐II), a synthetic cyclic heptapeptide analog of α‐melanocyte‐stimulating hormone (α‐MSH), in rat plasma by liquid chromatography/tandem mass spectrometry (LC/MS/MS). The analyte is recovered from plasma by solid‐phase extraction (SPE) and subsequently analyzed by LC/MS/MS. A SPE procedure using OASIS 96‐well plates is used for extraction of MT‐II from rat plasma. Using the described approach a limit of quantitation of 5 ng/mL was achieved in rat plasma. This level of sensitivity allowed the determination of pharmacokinetic parameters, following intravenous administration of MT‐II in rat. Copyright © 2002 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research